NEFL and Alzheimer disease: Interestingly, NfL levels seem to discriminate between different preclinical AD stages, such as Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) (Giacomucci et al., 2022), correlating with the disease progression; for this reason, it will be measured in all recruited subjects.